Skip to main content
Funded Studies

James B. Koprich, MA, PhD

Chief Scientific Officer at Atuka, Inc.

Location: Toronto ON Canada

James B. Koprich, MA, PhD, is chief scientific officer at Atuka Inc.; a scientific associate at Toronto Western Hospital, University Health Network; and visiting professor of neurology at Huashan Hospital, Fudan University. His research in Parkinson’s disease has largely focused on development and characterization of disease models and on pre-clinical evaluation of novel therapeutics for disease modification and reduction of dyskinesia. Dr. Koprich has conducted a number of studies contributing to the understanding of disease pathogenesis.


Associated Grants

  • Determining the Level of LRRK2 Inhibition Required for Therapeutic Efficacy

    2019


  • The Effects of a LRRK2 Inhibitor on Alpha-synuclein-induced Dopamine Deficits in a Pre-clinical Model of Parkinson's Disease

    2017


  • Characterization, Optimization and Validation of a Preformed Fibril Pre-clinical Model of Parkinson's Disease

    2016


  • Evaluation of LRRK2 Inhibition in a Pre-clinical Model of Parkinson's Disease

    2016


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.